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Vereinigung) in Nordbaden/Germany was available for analysis, covering the total 
regional population enrolled in Statutory Health Insurance (> 2.2 million lives for years 
2003 to 2009). Linear trend analyses were performed using regression analysis with the 
growth index of the prevalence rates of MHDs as dependent variable, and a coefficient 
of determination R2> 0.57 at a significance level p< 0.05 indicating a meaningful trend 
observation. Results: Overall, MHD diagnoses remained stable at rates between 31% 
and 34% during the observation period. MHDs were diagnosed more frequently in 
females (rates 37%-43%) than in males, whereas a significant increase was observed 
in males only (from 23.5% in 2003 to 28% in 2009). Most frequently diagnosed mental 
health problems in 2009 were depressive episodes, with an overall administrative 
12-months prevalence rate of 8.3%; unspecified somatoform disorders, 4.8%; harm-
ful use of tobacco, 3.4%; neurasthenia, 2.3%; and adjustment disorders, 2.2%. Age 
and gender specific trends will be reported in detail. For example, from 2003 to 2009, 
the administrative prevalence of attention-deficit/hyperactivity disorder (ADHD) 
increased by 79% (from 0.53% in 2003 to 0.95% overall; 6-12 years, 8.0%; 13-17 years, 
4.2%; adults from 0.04% in 2003 to 0.17% in 2009). Substantial prevalence increases 
were also found for dementia (significant for males only) and for disorders due to 
substance abuse (both males and females). ConClusions: The overall prevalence 
of MHDs did not increase during the observation period. Growing numbers for some 
disorders were compensated for by decreases of others.
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objeCtives: Lisdexamfetamine dimesylate (LDX) 50 and 70 mg demonstrated efficacy 
in terms of reduced binge eating days per week in adults with moderate to severe 
binge eating disorder (BED) in 2 randomized control trials (RCTs). This analysis aimed 
to determine the budgetary impact of introducing LDX for the treatment of BED in 
the United States (US). Methods: A 1-year budget impact analysis from a US health 
care payer’s perspective was performed. The patient population in the budget impact 
analysis was treated and diagnosed BED patients aged 18 years and older in the US. It 
was estimated that 17.5% of the budget impact patient population was treated with 
LDX in the first year of use. The base case analysis assumed a 12-week course of treat-
ment, based upon RCTs’ treatment duration. The model considered health care utiliza-
tion costs, drug costs and costs of adverse events. Inputs in the model were obtained 
from literature, trial data and an epidemiology survey. Results: Based on the inputs 
and assumptions, the total direct budgetary cost of treating BED within the adult US 
population, without LDX is estimated to be $241,699,596 over a 1-year time frame. If 
LDX were to treat 17.5% of the market, then the expected total budget would increase 
to around $242,768,676 which would be primarily due to the drug cost; however, there 
would be health care utilization costs savings of around $2,257,096. Introducing LDX 
would imply incremental average per member per year cost by $0.004. ConClusions: 
The budget impact of treating BED with LDX is modest; additional scientific evidence 
on the long-term economic burden of BED and the long-term efficacy of LDX therapy 
would help better understand the budgetary effect of LDX in BED.
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objeCtives: Lurasidone is an atypical antipsychotic with a favourable metabolic 
adverse event profile, indicated for treatment of adults with schizophrenia. The 
objective of this study was to perform an analysis of the impact of lurasidone on the 
National Health Service budget in the UK. Methods: A 3-year budget impact model 
was developed based on epidemiological estimates of total number of adults beginning 
antipsychotic therapy for schizophrenia. Costs considered included drug acquisition, 
weight gain, diabetes, and hospitalisations associated with relapse. Lurasidone 3-year 
uptake was based on projected displacement of the following atypical antipsychotics: 
olanzapine, risperidone, quetiapine and aripiprazole. Efficacy data were based on indi-
rect comparisons. Univariate sensitivity analysis was conducted to assess the impact 
of differential rates of displacement. Results: The current annual cost of schizophre-
nia in the population beginning antipsychotic therapy was approximately £17m. In 
year 1, treatment costs represented 7% of total costs; hospitalisations, weight gain and 
diabetes represented 90%, 3% and 1%, respectively. Base case uptake of lurasidone was 
assumed to be 5.5% annually. Assuming that lurasidone displaced only aripiprazole, 
lurasidone was associated with a net cumulative saving of £1.9m by year 3. Assuming 
lurasidone took market share equally from all considered atypicals, the net cumulative 
saving was £739k by year 3. In this equal displacement scenario, lurasidone uptake 
ranging from 2.5% to 11% resulted in estimated cumulative 3-year savings of £369k to 
£1.5m, respectively. ConClusions: Lurasidone was associated with cost savings in 
all scenarios. Estimates of annual budget impact ranged from cost savings of £369k to 
£1.9m. Cost savings were driven predominantly by reduced rates of hospitalisations 
associated with relapse, but also reduced costs of weight gain and diabetes.
PMH15
CoST-uTILITy ANd BudgET IMPACT ANALySES CoMPArINg LurASIdoNE 
wITH ArIPIPrAzoLE IN AduLTS wITH SCHIzoPHrENIA IN SCoTLANd
Rajagopalan K1, Trueman D2, Crowe L2, Patel P1, Loebel A3
1Sunovion Pharmaceuticals, Inc, Marlborough, MA, USA, 2Abacus International, Bicester, UK, 
3Sunovion Pharmaceuticals, Inc, Fort Lee, NJ, USA
only on particular supportive types, particular outcomes or solely on caregivers. 
Therefore a general systematic review was conducted investigating effectiveness 
of different types of supportive strategies on at least well-being of the caregiver 
or the care-recipient. Methods: A systematic literature search was conducted 
in Web of Science and PubMed. An adapted version of the Downs and Black (1998) 
checklist was used to assess methodological quality. Results: Forty-six papers met 
inclusion criteria. Although 87% of the interventions were to some extent effective, 
methods and findings were rather inconsistent. Psychoeducational interventions 
generally lead to positive outcomes for caregivers, decrease behavioral problems 
and delay permanent institutionalization of care-recipients. Cognitive behavioral 
therapy decreases dysfunctional thoughts among caregivers, and occupational ther-
apy decreases behavioral problems among patients. In general, those interventions 
tailored on individual level generate better outcomes. Comparative research on 
respite care was very rare. ConClusions: Despite methodological inconsistency, 
supporting caregivers appears to be an effective strategy often improving well-
being of caregiver or care-recipient and resulting in additional benefits for society. 
However, there is a need for more research on the (cost)-effectiveness of respite care.
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objeCtives: To examine the patterns of drug prescription for the treatment 
of attention-deficit/hyperactivity disorders in Japanese children and adoles-
cents. Methods: We conducted a cross-sectional survey on December 1, 2013, 
on patients aged 19 or less in two national mental hospitals. Patients who were 
prescribed at least one drug for the treatment of attention-deficit/hyperactivity 
disorders (anti-ADHD drug) were analyzed. Data were extracted on gender, age, 
and types and doses of psychotropic drugs. Data on the patients’ diagnoses were 
not collected. Results: The patients included 87 males and 26 females, with a 
mean age (standard deviation) of 12.4 (2.8) years. Of these 113 patients, 70 (61.9%) 
patients received the psychostimulant OROS methylphenidate (OROS-MPH) 
only, 26 (23.0%) received atomoxetine (ATMX), a selective noradrenalin reuptake 
inhibitor only, and 17 (15.0%) received the combination OROS-MPH/ATMX therapy. 
Antipsychotics were concurrently prescribed in 51 (45.1%) patients. Mood stabilizers 
were co-prescribed in 31 (27.4%) cases. Antidepressants were co-prescribed in 8 
(7.1%) patients. Anxiolytics/hypnotics were concurrently prescribed in 23 (20.4%) 
patients. ConClusions: Nearly one-sixth of patients, aged 19 or less and treated 
with anti-ADHD drug therapy in Japanese mental hospitals, were prescribed OROS-
MPH/ATMX combination therapy. In addition, almost half of these young patients 
on anti-ADHD drugs were co-prescribed antipsychotics.
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objeCtives: To assess the prevalence of sleeping pills consumption among Brazilian 
adults and its association with depressive symptoms. Methods: This is an analysis 
of Brazilian National Health Survey performed in 2013. Primary outcome included 
self-reported sleeping pills use in last two weeks. We assessed five independent 
variables: number of days that sleeping pills were used; self-medication practice for 
sleeping pills; depressive symptoms (measured by the Patient Health Questionnaire 
PHQ-9 for depression); sex and age. To evaluate the association between the severity 
of depression symptoms and sleeping pills consumption we calculated prevalence 
ratio (PR) adjusted for sex and age through a Poisson regression with robust variance. 
Sensitivity analysis was performed by re-sampling technique (bootstrap). Complex 
sample design was balanced in all analysis in STATA software, version 11. Results: 
44,072 individuals were included. 62.1% were women and had a mean age of 45.6 ± 
29.7. Taking sleeping pills in the last two weeks was reported by 8.5% (95% CI: 8.0-
9.0%), of which 9.7% (95% CI: 8.2-11.3%) took without medical advice. Mean duration 
of treatment in this period was 9.9 ± 8.3 days. Depressive symptoms were reported 
as: minimal by 13.9%, minor by 5.1%, moderately severe by 2.2%, and severe major 
symptoms by 1.1%. Compared to people without depressive symptoms, the PR of 
sleeping pill use was: 3.6 (95% CI: 3.1-4.1) for minimal depressive symptoms, 5.2 
(95% IC: 4.4-6.1) for minor depressive symptoms; 6.9 (95% CI: 5.8-8.2) for moderately 
severe depressive symptoms; and 9.2 (95% CI: 7.6-11.2) for severe major depressive 
symptoms (p < 0.001 for all calculations, without changes in the sensitivity analy-
sis). ConClusions: One out of ten Brazilians took pills to induce sleep in previ-
ous two weeks, and this consumption is strongly associated with the prevalence 
of depressive symptoms. Individuals that use sleep medicines should search for 
psychiatrist aid to evaluate possible co-existence of depression.
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objeCtives: The burden of mental health disorders (MHDs) is believed to be substan-
tial and increasing, but robust data on real-life diagnosis trends are rare. The objective 
of the present analysis was to explore changes in the administrative 12-months preva-
lence rates of MHDs from 2003 to 2009 in Nordbaden, Germany. Methods: The com-
plete claims database of the organization of registered physicians (Kassenaerztliche 
